These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28874039)

  • 1. Hepatic and Splenic Volumetry Could Be Used as an Imaging Parameter to Evaluate Fibrosis Grades of the Diffuse Liver Disease Including Nonalcoholic Fatty Liver Disease.
    Jeong WK
    Gut Liver; 2017 Sep; 11(5):577-578. PubMed ID: 28874039
    [No Abstract]   [Full Text] [Related]  

  • 2. Shear Wave Elastography for Assessment of Steatohepatitis and Hepatic Fibrosis in Rat Models of Non-Alcoholic Fatty Liver Disease.
    Kang BK; Lee SS; Cheong H; Hong SM; Jang K; Lee MG
    Ultrasound Med Biol; 2015 Dec; 41(12):3205-15. PubMed ID: 26349582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
    Park CC; Nguyen P; Hernandez C; Bettencourt R; Ramirez K; Fortney L; Hooker J; Sy E; Savides MT; Alquiraish MH; Valasek MA; Rizo E; Richards L; Brenner D; Sirlin CB; Loomba R
    Gastroenterology; 2017 Feb; 152(3):598-607.e2. PubMed ID: 27911262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease: portal hypertension due to outflow block in patients without cirrhosis.
    Hirooka M; Koizumi Y; Miyake T; Ochi H; Tokumoto Y; Tada F; Matsuura B; Abe M; Hiasa Y
    Radiology; 2015 Feb; 274(2):597-604. PubMed ID: 25302830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment using computed tomography volumetry.
    Fujita N; Nishie A; Asayama Y; Ishigami K; Ushijima Y; Takayama Y; Okamoto D; Shirabe K; Yoshizumi T; Kotoh K; Furusyo N; Hida T; Oda Y; Fujioka T; Honda H
    World J Gastroenterol; 2016 Oct; 22(40):8949-8955. PubMed ID: 27833386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis.
    Yu R; Shi Q; Liu L; Chen L
    BMC Gastroenterol; 2018 Apr; 18(1):51. PubMed ID: 29673321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases.
    Ochi H; Hirooka M; Koizumi Y; Miyake T; Tokumoto Y; Soga Y; Tada F; Abe M; Hiasa Y; Onji M
    Hepatology; 2012 Oct; 56(4):1271-8. PubMed ID: 22488593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.
    Garg H; Aggarwal S; Shalimar ; Yadav R; Datta Gupta S; Agarwal L; Agarwal S
    Surg Obes Relat Dis; 2018 Jan; 14(1):81-91. PubMed ID: 29126863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low vitamin D status is associated with advanced liver fibrosis in patients with nonalcoholic fatty liver disease.
    Yang BB; Chen YH; Zhang C; Shi CE; Hu KF; Zhou J; Xu DX; Chen X
    Endocrine; 2017 Feb; 55(2):582-590. PubMed ID: 27796814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock?
    Stine JG; Rinella ME
    Am J Gastroenterol; 2017 May; 112(5):752-754. PubMed ID: 28469217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Tada T; Kumada T; Toyoda H; Saibara T; Ono M; Kage M
    Biomarkers; 2018; 23(4):328-334. PubMed ID: 29308929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of fibrosis during the development of fatty liver in rabbits using real-time shear-wave elastography.
    Lu YP; Wei J; Xu LR; Tang YY; Yuan Y; Zhang Y; Li YY
    J Huazhong Univ Sci Technolog Med Sci; 2014 Dec; 34(6):921-928. PubMed ID: 25480592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do we need controlled attenuation parameter adjustment for fibrosis estimation in nonalcoholic fatty liver disease patients?
    Karlas T; Beer S; Babel J; Busse H; Schaudinn A; Linder N; Wiegand J; Petroff D
    Hepatology; 2017 Jun; 65(6):2126-2128. PubMed ID: 28103641
    [No Abstract]   [Full Text] [Related]  

  • 18. Devilish Effects of Taz in Nonalcoholic Steatohepatitis.
    Friedman SL; Lee YA
    Cell Metab; 2016 Dec; 24(6):771-772. PubMed ID: 28068221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
    Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
    Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
    Kaswala DH; Lai M; Afdhal NH
    Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.